Checkpoint Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Checkpoint Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Checkpoint Therapeutics Inc Strategy Report
- Understand Checkpoint Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops, and commercializes novel treatments for solid tumor cancers. Its lead product candidate, CK-101 molecule is in Phase I clinical trials for the treatment of patients with positive epidermal growth factor receptor (EGFR). The company’s other lead product candidate CK-301, is an anti-PD L1 antibody intended for the treatment of patients with non-small cell lung cancer (NSCLC) and other solid tumors. Checkpoint Therapeutics’ other pipeline products include a portfolio of human immuno-oncology agents and targeted anti-cancer agents intended for the treatment of multiple types of cancer including renal cell carcinoma, EGFR mutation-positive NSCLC and multiple forms of cancer. The company also works in partnership with other pharmaceutical companies to co-develop its antibodies. Checkpoint Therapeutics is headquartered in New York, the US.
Headquarters
United States of America
Address
95 Sawyer Road, Suite 110, Waltham, Massachusetts, 02453
Website
checkpointtx.com
Telephone
1 781 6524500
No of Employees
23
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CKPT (NASD)
Revenue (2022)
$103,000
-46.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
17.2%
(2022 vs 2021)
Market Cap*
$51.2M
Net Profit Margin (2022)
XYZ
-54.3%
(2022 vs 2021)
* As of and is in US$
Checkpoint Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CK-301 anti- PDL1- for Lung Cancer and other tumors |
| CK-101 EGFR Inhibitor Program –for NSCLC |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In January, the company submitted Biologics License application to the FDA. |
| 2023 | Regulatory Approval | In March, the FDA accepted the company’s Biologics License Application. |
| 2022 | Others | In May, the company received Pediatric Investigation Plan Waivers from European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency. |
Competitor Comparison
| Key Parameters | Checkpoint Therapeutics Inc | Merck & Co Inc | Bristol-Myers Squibb Co | Gilead Sciences Inc | Telix Pharmaceuticals Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Australia |
| City | Waltham | Kenilworth | Princeton | Foster City | Melbourne |
| State/Province | Massachusetts | New Jersey | New Jersey | California | Victoria |
| No. of Employees | 23 | 72,000 | 34,100 | 18,000 | 234 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael S. Weiss | Chairman | Executive Board | 2015 | 57 |
| James F. Oliviero | Director; Chief Executive Officer; President | Executive Board | 2015 | 47 |
| Garrett Gray | Chief Financial Officer | Senior Management | 2020 | 35 |
| Neil Herskowitz | Director | Non Executive Board | 2015 | 66 |
| Lindsay A. Rosenwald, M.D. | Director | Non Executive Board | 2014 | 68 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward